ClinicalTrials.gg
CompletedNCT05993975Updated Oct 31, 2023

Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine

A Phase 4 interventional study of Bupivacain 0.5% and Dexmedetomidine Hydrochloride in Post Operative Pain, sponsored by Sindh Institute of Urology and Transplantation. Completed at 1 site in Pakistan. Open to male participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-31.

Sponsored by Sindh Institute of Urology and Transplantation · Phase 4, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 8 months ago, and no results have been posted to the registry.
  • Registered 1 year 11 months after the study started (first participant enrolled Jul 2021, registered Jul 2023).
Phase
Phase 4
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
Male
01

Study summary

Patients will be enrolled in one of the two groups using a computer-generated random number table: Group I will receive 1.5 ml of 0.5% hyperbaric bupivacaine (7.5 mg). Group II will receive 1.2 mL of 0.5% hyperbaric bupivacaine (6 mg) along with 0.3 mL (3 μg )of dexmedetomidine (total 1.5 mL).

Read the detailed description

After approval of the synopsis and permission from the hospital ethics committee, all patients meeting the inclusion criteria will be included in the study. Patients will be instructed not to consume solid food after midnight before surgery and to take clear liquids up to 2 hours before surgery. Using a computer-generated random number table, patients will be enrolled in one of the two groups: Group I will receive 1.5 ml of 0.5% hyperbaric bupivacaine (7.5 mg). Group II will receive 1.2 mL of 0.5% hyperbaric bupivacaine (6 mg) along with 0.3 mL (5 μg )of dexmedetomidine (total of 1.5 mL). They will be randomly allocated into two groups using the sealed envelope technique by a person blinded to the procedure. The study medication will be prepared by an anaesthesiologist not involved in the study and another anaesthesiologist performing the spinal block will record the intraoperative and postoperative data. On arrival at the Operating Room (OR) monitors like a non-invasive blood pressure monitor (NIBP), peripheral oxygen saturation monitor (SpO2), and electrocardiography monitor (ECG) having lead II will be attached. All the baseline values of blood pressure (SBP, DBP, and MAP), heart rate and rhythm, and SPO2 will be observed and recorded. An intravenous (IV) line will be established with an 18-gauge cannula. The study drug solutions will look identical. For Group I, 7.5 mg(1.5 mL) of 0.5% hyperbaric bupivacaine hydrochloride will be drawn in a 3 mL BD syringe. For Group II, 6mg (1.3 mL) of 0.5% hyperbaric bupivacaine hydrochloride will be drawn in a 3 mL BD syringe. By using an insulin syringe, 0.3 mL (3 μg) of Dexmedetomidine (preservative free) 100 μg/mL will be added to the 6 mg (1.3 mL) of hyperbaric bupivacaine under complete aseptic conditions to bring the total volume to 1.5 mL. The total volume of drug solutions will be 1.5 mL in each group.

Local infiltration of the skin with 2mL of 2% lidocaine will be done to decrease the discomfort caused by the spinal needle. A spinal puncture will be performed at L3-L4 or L4-L5 with a midline approach using a 25-gauge Quincke needle in the sitting position. After verification of clear and free flow of cerebrospinal fluid, the drug will be administered and the patients will be placed in the supine position Vitals will be monitored Heart Rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), respiratory rate (RR), oxygen saturation (SpO2) for every 5 minutes till the end of surgery. If mean arterial pressure (MAP) decreases below 65 mmHg or the Heart rate falls below 65 beats per minute then intravenous vasopressors will be given. The sensory block levels will be checked on the bilateral mid-clavicular line with a pin prick with a blunt needle every 2 min from the time of drug injection until the sensory level achieves up to T10 level.

In contrast, the motor block will be assessed using the modified Bromage scale. The surgeon will be asked to start the surgery when the sensory block has reached the T10 level. After completion of the surgery, the patient will be shifted to the PACU and monitored for 3 hours with continuous ECG monitoring and intermittent non-invasive blood pressure monitoring at 5-minute intervals. All untoward events like shivering, nausea vomiting, sedation, and respiratory depression will be monitored and recorded in the operating room as well as in the recovery room.

All data will be recorded on Performa attached as Annex A after the consultant anesthetist confirms.

02

Conditions studied

  • Post Operative Pain

Browse trials for

03

In context

Pain, Postoperative

5,224 studies on the registry are indexed under Pain, Postoperative; 1,154 are open to participants now.

This study's enrollment of 108 is above the median of 75 across 4,457 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Sindh Institute of Urology and Transplantation is the lead sponsor of 18 studies on the registry; 6 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ASA I to ASA II
  • Age 50 to 80 years old
  • Height between 155cm and 175 cm

Exclusion criteria

Exclusion Criteria:

  • History of spine surgery or the presence of an infectious focus on the back
  • Patient's refusal to undergo a spinal anaesthesia
  • Hypersensitivity to bupivacaine or dexmedetomidine
  • Patients taking drugs of abuse or narcotic analgesics
  • Diabetic neuropathy
  • History of bleeding disorders
  • Oral/intravenous anticoagulant therapy
  • History of arrhythmias or labile hypertension
  • Unco-operative patients
  • Hearing defect
  • ASA III and IV
  • Central or peripheral nervous system disorders
  • Severe hypovolemia
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Active comparator
    BUPIPURE

    Hyperbaric Bupivacaine 0.5% (1.5 ml/7.5 mg) to be given intrathecally Total volume 1.5 mL

    Drug: Bupivacain 0.5%

  • Experimental
    BUPI-DEX

    Hyperbaric Bupivacaine 0.5% (1.2 ml/6 mg)+Dexmedetomidine (0.3 mL) 3 microgram intrathecally. Total volume 1.5 mL

    Drug: Bupivacain 0.5% · Drug: Dexmedetomidine Hydrochloride

Interventions

  • Bupivacaine hydrochloride was given without any adjuvant

    Also known as: Pure Bupivacain 0.5%

  • Use of Dexmedetomidine Hydrochloride 5 micrograms (1 mL) as an adjuvant with bupivacaine hydrochloride

    Also known as: Dexmedetomidine 5 microgram

06

What researchers measure

Primary outcomes

  1. Height of sensory block

    Dermatome level having absence of cold sensation

    Time frame: 0 to 4 hours

  2. Motor block

    According to Bromage scores Grade Criteria I Free movement of legs and feet II Just able to flex knees with free movement of feet III Unable to flex knees, but with free movement of feet IV Unable to move legs or feet we need paralysis of both legs (Bromage score IV) for surgery

    Time frame: 0 to 4 hours

  3. Time for 2 segment regression of sensory block

    Dermatome level having absence of cold sensation

    Time frame: 0 to 4 hours

  4. Heart rate

    By anaesthesia ECG monitor

    Time frame: 0 to 4 hours

  5. Mean Blood pressure

    Non invasive blood pressure monitoring devise

    Time frame: 0 to 4 hours

Secondary outcomes

  1. Shivering

    Bedside Shivering Assessment Score (BSAS) grade 0, if there is no shivering grade 1 if there is no muscle contraction but mild fasciculation of face or neck or peripheral vasoconstriction but no visible shivering, grade 2 if there is a visible muscular activity in only one muscle group, grade 3 if the muscular activity is in more than one muscle group but not generalized grade 4 if gross muscular activity involving the entire body. Grade 0 is better, increase in grade (0 -\> 4) means worsening

    Time frame: 0 to 4 hours

07

Study locations

1 site
  • Syed Muhammad Abbas
    Karachi, Sindh 74200, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05993975
Lead sponsor
Sindh Institute of Urology and Transplantation
Responsible party
Syed Muhammad Abbas (Associate Professor, Department of Anaesthesia, Sindh Institute of Urology and Transplantation) — Principal investigator
First posted
Aug 16, 2023
Start date
Jul 20, 2021
Primary completion
Feb 18, 2022
Completion
Feb 18, 2022
Last update
Oct 31, 2023

Study contacts

Ali A Lanewala, MD, PhD
study director · Sindh Institute of Urology & Transplantation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion